Targeted cancer therapy

Patent metadata

Field	Value
Publication number	US-11207339-B2
Application number	US-201615772134-A
Country	US
Kind code	B2
Filing date	Oct 28, 2016
Priority date	Oct 30, 2015
Publication date	Dec 28, 2021
Grant date	Dec 28, 2021

Abstract

Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.

First claim

What is claimed is:

1. A method comprising
(i) delivering to a tumor of a subject an engineered nucleic acid encoding an antigen, wherein the engineered nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, wherein the tumor expresses the antigen and
(ii) administering to the subject an immune cell expressing a chimeric receptor that binds to the antigen; wherein the antigen comprises an epitope of CD19, CD20, CD21, CD22, CD45, BCMA, HER2 (ErbB2), EGFRvIII, B7-H3, B7-H6, FAP, FRa, EpCAM, GD2, ROR1, PSMA, or IL13Ralpha2, wherein the immune cell binds to the expressed antigen, thereby resulting in killing of the tumor.

2. The method of claim 1 , wherein the tumor antigen is or comprises an epitope of CD19.

3. The method of claim 2 , wherein the tumor antigen is selected from full length CD19, a fragment of CD19, or a linear epitope of CD19.

4. The method of claim 1 , wherein the engineered nucleic acid encoding the antigen is encapsulated within the tumor-selective vehicle.

5. The method of claim 1 , wherein tumor-selective vehicle is a virus or a pseudovirus.

6. The method of claim 5 , wherein the tumor-selective vehicle is an oncolytic virus, a chimeric virus, a virus that is modified to target tumor cells, a papillomavirus, or a pseudovirus.

7. The method of claim 6 , wherein the tumor-selective vehicle is an oncolytic virus selected from an adenovirus, a vaccinia virus, a Sindbis virus, a Seneca valley virus, a Coxsackie virus, a measles virus, a reovirus, a vaccinia virus, a Newcastle disease virus, a vesicular stomatitis virus, a herpes simplex virus, a poliovirus, and a parvovirus.

8. The method of claim 6 , wherein the tumor-selective vehicle is a chimeric virus obtained from engineering adeno-associated viruses and bacteriophages that display tumor selective peptides.

9. The method of claim 6 , wherein the tumor-selective vehicle is an adeno-associated virus (AAV) that is modified to target tumor cells.

10. The method of claim 6 , wherein the tumor-selective vehicle is a human papillomavirus, a modified human papillomavirus, a non-human papillomavirus, or a modified non-human papillomavirus.

11. The method of claim 1 , wherein tumor-selective vehicle is or comprises a natural polymer, a synthetic polymer, a cationic peptide, a cell-penetrating peptide, a biodegradable nanoparticle, a liposome, a lipoplex, a polyplex, a micelle, a dendrimer, a gel, a mucoadhesive or a silicon nanoneedle.

12. The method of claim 1 , wherein the tumor-selective vehicle comprises a tumor-targeting agent.

13. The method of claim 1 , wherein the engineered nucleic acid encoding an antigen is a deoxyribonucleic acid (DNA) or a ribonucleic acid (RNA).

14. The method of claim 13 , wherein the engineered nucleic acid encoding an antigen is a messenger RNA (mRNA).

15. The method of claim 1 , wherein the immune cell is leukocyte.

16. The method of claim 1 , wherein the immune cell is a T cell, a B cell, an NK cell, an NKT cell, or a dendritic cell.

17. The method of claim 1 , wherein the tumor-selective vehicle is delivered via a parenteral, enteric or topical route, or wherein the engineered nucleic acid is injected into the tumor.

Assignees

• Us Health
• Aleta Biotherapeutics Inc

Inventors

• Lobb Roy
• Rennert Paul David
• Schiller John Todd

Classifications

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2121/00

  Preparations for use in therapy · CPC title

• A61K2039/5158

  Antigen-pulsed cells, e.g. T-cells · CPC title